Form 4: Verastem Director Anil Kapur Receives Significant Equity Grants, Aligning Interests with Shareholders

Verastem, Inc. Director Anil Kapur was granted 8,333 Restricted Stock Units (RSUs) and options to purchase 12,500 shares of common stock, vesting over approximately one year, as reported in a recent SEC Form 4 filing.

Summary

• Anil Kapur, a Director of Verastem, Inc. (VSTM), reported changes in beneficial ownership of the company's securities.
• On May 22, 2025, Mr. Kapur acquired 8,333 shares of Common Stock through Restricted Stock Units (RSUs) at a price of $0.00 per share.
• Following this transaction, Mr. Kapur beneficially owns 16,666 shares of Common Stock.
• Additionally, on May 22, 2025, Mr. Kapur was granted stock options to acquire 12,500 shares of Common Stock with an exercise price of $7.48 per share.
• The RSUs and stock options both vest in twelve equal installments.
• The first eleven installments will vest on the last day of each month from June 2025 to April 2026.
• The final installment will vest on the earlier of the day before the 2026 Annual Meeting of Stockholders or May 31, 2026.
• Vesting for both grants is contingent upon Mr. Kapur's continued service as a director of Verastem, Inc.
• The stock options have an expiration date of May 22, 2035.

Sentiment

Score: 7

Explanation: The document reports a routine equity grant to a director, which is generally positive as it aligns interests. It does not contain negative news or significant operational updates.

Positives

• The granting of RSUs and stock options to a director aligns management's interests with those of shareholders, as the value of these grants is tied to the company's stock performance.
• Equity compensation is a common practice to incentivize long-term commitment and performance from directors.

Risks

• The vesting of both the RSUs and stock options is conditional on Anil Kapur's continued service as a director of Verastem, Inc., meaning the benefits are not guaranteed if his directorship ceases.

Future Outlook

The equity grants to Director Anil Kapur, with their vesting schedule extending into 2026, indicate an expectation of his continued service on the board, aligning his long-term incentives with the company's performance.

Industry Context

The granting of equity compensation, such as RSUs and stock options, to directors is a standard practice across publicly traded companies, particularly in the biotechnology and pharmaceutical sectors like Verastem, Inc. This method is widely used to attract, retain, and incentivize qualified board members by linking their personal financial success to the company's stock performance and long-term value creation.

Corporate Governance

Related Party Transactions

• The equity grants to Anil Kapur, a director of Verastem, Inc., constitute a related party transaction as it involves compensation provided by the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: The equity grants are designed to align the director's incentives with shareholder value creation, potentially leading to better long-term performance.
• Employees: While not directly impacted, the compensation structure for directors can reflect the company's overall approach to incentivizing key personnel.

Next Steps

• Anil Kapur's continued service as a director of Verastem, Inc. is required for the vesting of his RSUs and stock options.
• The company will hold its 2026 Annual Meeting of Stockholders, which is a key date for the final vesting installment.

Key Dates

Keywords

Verastem, VSTM, Form 4, Insider Transaction, Equity Grant, Restricted Stock Units, RSU, Stock Option, Director Compensation, Beneficial Ownership